Look left NASDAQ:LMNL on daily.
All the pumps followed by the dumps next day.
Close below open - 78%
Avg. fade - 17%
Avg. low - 28%
We aim 23% on the backside here.
I called Liminal BioSciences Inc (NASDAQ:LMNL) recently at $4.40 as a potential big runner due to the PDUFA catalyst. On Friday, just a few minutes before the close, the stock was halted and the U.S. Food & Drug Administration (FDA) announced the approval of Ryplazim® (plasminogen, human-tvmh) ("Ryplazim®") for the treatment of patients with plasminogen...
DISCLAIMER: I'm not a certified or licensed financial advisor, securities trader, or securities broker; and, this is not intended as financial or securities advice.
Hopefully, my observations are improving. Using two separate 2 over 2 layouts for my version of multiple time frame analysis . Tracking intraday trends in one (5s, 2m, 20m, 2h). Tracking multi-day...
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on discovery, development, and commercialization of novel small molecule drug candidates for the treatment of patients suffering from respiratory fibrotic diseases and other fibrotic or inflammatory diseases that have high unmet medical needs
85% below the July peak of last year and 99% below its all-time high.
Orbiting a major support level around $4.
A capital injection began in mid-November that is still not properly reflected in price.
Stochastic at the oversold point and RSI close to touching it.
It could give the surprise of giving a significant bounce to the marked lines.
The risk is that...
LMNL is a biopharma company of no incredible significance, but I thought the chart patterns were worth sharing. First and foremost, look at the runup in volume! Trapped beneath downtrend resistance, I'd venture to guess it's undergoing heavy accumulation. If it breaks through downtrend resistance, upside targets are in the neighborhood of $10 and $15 -- full...
Looks to continue its slide, possibly towards $3.21 or lower. Hard to find where support might wind up here? Nothing good coming out of that quarterly report for investors to bite into. Revenue dropped 41% YOY, the drawdown on their entire line of credit 29.1mil, growing debt, and the issuance of more convertible debt...not helping here. For the moment this...
Huge volume here, looks to have bottomed, I would say definitely oversold at $3.96, however, let's see what happens after the bell. This could quickly retrace at least to $10.50
Catalyst:
-Trump and his mention of plasma
-Full WSJ article on Convalescent Plasma
-Hyping on twitter
TrustYourDD@TrustYourDD
Possible sounds like an FDA approval is gonna drop PR any time now and $LMNL $ADMA $TAK and others have been working on plasma collaborations might be tomorrow might be tonight
www.wsj.com
Liminal BioSciences Commences Collection of Convalescent Plasma from COVID-19 Recovered Donors
Recent published studies have indicated immune globulin and hyperimmune globulin therapy to have the potential to be one of the treatment options for patients with COVID-19. We are proud to be collecting COVID-19 convalescent plasma to be potentially used in the...
